Addex Initiates Phase IIa Clinical Trial of Dipraglurant-IR in Parkinson's Disease Levodopa-Induced Dyskinesia (PD-LID)

Second Phase IIa trial to begin this quarter with Addex allosteric modulators

06-Apr-2011 - Addex Pharmaceuticals announced the initiation of a Phase IIa clinical trial to evaluate dipraglurant in patients with Parkinson's disease levodopa-induced dyskinesia (PD-LID), a debilitating movement disorder caused by long-term treatment with levodopa, the gold standard therapy for Parkinson's ...

Addex Partner Starting Clinical Schizophrenia Trial

05-Apr-2011 - Addex Pharmaceuticals announced the start of a Phase IIa clinical trial of ADX71149 for the treatment of schizophrenia. ADX71149, a positive allosteric modulator (PAM) of metabotropic glutamate receptor 2 (mGluR2), is the result of a successful discovery collaboration and licensing deal announced ...

Addex Awarded Michael J. Fox Foundation Grant for ADX48621 to treat Levodopa-Induced Dyskinesia in Parkinson's

10-Sep-2010 - Addex Pharmaceuticals Ltd announced that it has been awarded a $900,000 grant from the Michael J. Fox Foundation (MJFF) to help fund a Phase II study of ADX48621 for the treatment of Parkinson’s disease levodopa-induced dyskinesia (PD-LID). Patients with PD can live 10-20 years after diagnosis; ...

Addex drug-candidate effective in Alzheimer's disease model

03-Sep-2010 - Addex Pharmaceuticals Ltd announced that it has observed efficacy in a model of Alzheimer's disease using a recently discovered orally-available drug-candidate. The proprietary molecule specifically inhibits a receptor subtype called the metabotropic glutamate receptor 2 (mGluR2) via negative ...

Addex Partner Completes ADX71149 Phase I Program

26-Aug-2010 - Addex Pharmaceuticals Ltd announced that the Phase I studies required to commence Phase II testing of ADX71149 have been satisfactorily completed. Subject to regulatory authorizations, Phase IIa studies in schizophrenia and anxiety, are scheduled to start enrolling patients in the first quarter ...

Addex drug candidate effective in osteoarthritis pain model

15-Jul-2010 - Addex Pharmaceuticals Ltd. announced today that its preclinical drug candidate ADX71943 was effective in a model of osteoarthritis pain. ADX71943 is a potent and selective positive allosteric modulator of gamma-aminobutyric acid subtype B (GABA-B) receptors. GABA-B receptors mediate the slow, ...

Addex: ADX71943 Demonstrates Analgesic Effects in Pain Models

09-Feb-2010 - Addex Pharmaceuticals announced that ADX71943 has demonstrated statistically significant analgesic-like effects in three preclinical models of pain. In the first model, ADX71943 reversed complete Freund adjuvant (CFA)-induced reductions in withdrawal thresholds in a dose-related manner, with a ...

Addex ADX10059 Monotherapy is Effective on GERD Symptoms in Phase IIb Clinical Trial

17-Nov-2009 - Addex Pharmaceuticals announced that it achieved statistically significant efficacy on the primary endpoint, increasing the number of symptom free days in the Phase IIb trial of ADX10059 as a monotherapy in patients with gastroesophageal reflux disease (GERD), the cause of heartburn and other ...

Addex' ADX10059 has potential for Parkinson's disease levodopa induced dyskinesia (PD-LID)

15-Sep-2009 - Addex Pharmaceuticals reported that its lead product, ADX10059, which is nearing completion of Phase IIb testing in gastroesophageal reflux disease (GERD) and migraine prevention, also has demonstrated significant potential in a non-human primate model of Parkinson's disease levodopa induced ...

Addex Partner Starts First-Ever Clinical Trial of an mGluR Positive Allosteric Modulator

Novel Approach Has Potential for Treatment of Multiple CNS Disorders

25-Jun-2009 - Addex Pharmaceuticals announced that its partner Ortho-McNeil-Janssen Pharmaceuticals Inc. (OMP) has started Phase I testing of ADX71149, a metabotropic glutamate receptor 2 (mGluR2) positive allosteric modulator (PAM). This product, which has potential to treat schizophrenia, anxiety, depression ...